bluebird bio downgraded by Bank of America, shares tumble
Portfolio Pulse from
bluebird bio Inc (NASDAQ:BLUE) shares fell over 11% after Bank of America downgraded the stock to 'Neutral' and slashed the price target from $3 to $0.50. The downgrade is due to concerns about the slow ramp-up and lower peak revenue of its key product, Lyfgenia, for sickle cell disease.
November 15, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
bluebird bio's stock dropped over 11% following a downgrade by Bank of America to 'Neutral'. The price target was reduced from $3 to $0.50 due to concerns about the slow ramp-up and lower peak revenue of its product Lyfgenia for sickle cell disease.
The downgrade by a major financial institution like Bank of America is significant, especially with a drastic reduction in the price target. This indicates a lack of confidence in the company's near-term prospects, particularly concerning its key product Lyfgenia. The market reacted negatively, as evidenced by the 11% drop in share price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100